Is There a Generic Ozempic? Generic Semaglutide and Liraglutide in 2026


Published November 22, 20268 min read

Reviewed by the MaxLife operations team. FDA records and prices checked in November 2026 and subject to change.


Key Takeaways

  • Apotex's semaglutide injection got a tentative FDA approval on April 7, 2026 in the strengths of Ozempic's pens, but it can't be sold until patent issues are resolved.
  • By November 2026 the FDA had approved 12 generic liraglutide applications: 9 rated to Victoza and 3 to Saxenda.
  • Generic semaglutide has been sold in Canada since May 2026, but it isn't approved for the US, and importing it for personal use is generally not allowed.
MaxLife header: is there a generic Ozempic? None on sale in the US, tentative FDA approval April 7, 2026, main semaglutide patent ends December 5, 2031

No. As of November 2026, there is no FDA-approved generic of Ozempic® (semaglutide) on sale in the US, and there is none of Wegovy® or Rybelsus® either. The FDA gave one company, Apotex, a tentative approval for a generic semaglutide injection on April 7, 2026, but a tentative approval does not allow sales. The main semaglutide patent in the FDA's Orange Book runs to December 5, 2031. Compounded semaglutide is not a generic. The GLP-1 medicine that does have FDA-approved generics is liraglutide, the daily injection sold as Victoza® and Saxenda®.

Semaglutide productCan you buy it in the US?
Ozempic, Wegovy, Rybelsus (FDA-approved brands from Novo Nordisk)Yes, with a prescription
Apotex's generic semaglutide injection (tentative FDA approval)No, not until final approval
Compounded semaglutide (made by a licensed pharmacy for one patient, not FDA-approved)With a prescription, but it is not a generic
Generic semaglutide sold in Canada (approved by Health Canada, not the FDA)No

What Is the Generic Name for Ozempic?

Ozempic's generic name is semaglutide. That is the medicine's official name, printed on the label under the brand name. Wegovy and Rybelsus are semaglutide too: Ozempic is approved for adults with type 2 diabetes, and Wegovy is the semaglutide brand approved for weight management (NovoCare).

A generic name is not a generic drug. Today every FDA-approved semaglutide product in the US comes from Novo Nordisk. Other semaglutide sold here is compounded or unapproved.

What Makes a Drug a Generic?

A generic is a copy of a brand-name drug that the FDA has approved through an abbreviated new drug application (ANDA). According to the FDA, the company must show that its product:

  • matches the brand in active ingredient, strength, dosage form (such as an injection) and route;
  • is bioequivalent, meaning it delivers the medicine into the body at the same rate and to the same extent;
  • is made under the same strict manufacturing standards;
  • carries the brand's label, with certain exceptions.

Generic makers don't repeat the brand's clinical trials, which is a big reason generics cost less. The FDA's Orange Book then rates each approved generic as therapeutically equivalent to the brand it copies.

Has the FDA Approved a Generic Semaglutide?

Not a final approval. On April 7, 2026, the FDA gave Apotex Inc. a tentative approval for semaglutide injection (ANDA 220314) in 2 mg/3 mL, 4 mg/3 mL and 8 mg/3 mL strengths, which match the strengths the Orange Book lists for Ozempic's multi-dose pens.

The FDA explains in its Drugs@FDA glossary that a tentative approval means the generic is ready, but final approval waits "until all patent or exclusivity issues have been resolved." A tentative approval "does not allow the applicant to market the generic drug product." When we checked Drugs@FDA in November 2026, the Apotex application was still listed as a tentative approval, and no other semaglutide generic had any FDA approval.

When Will Ozempic Go Generic in the US?

Not before the patent issues that block a generic are resolved, and the FDA does not announce a date. The Orange Book lists these patents for the three semaglutide brands (checked November 2026):

PatentListed to expire
US 8,129,343: semaglutide itself, for all three brandsDecember 5, 2031
Later Ozempic and Wegovy patents: product forms and approved usesAs late as February 17, 2041
Later Rybelsus patents: tablet forms and approved usesAs late as February 1, 2039

December 5, 2031 is the date the main patent allows. Generic makers can challenge later patents, so the first launch could be set by how those disputes end rather than by the last date on the list. The FDA itself warns that an Orange Book listing doesn't tell you exactly what a patent covers. Even after 2031, a generic still needs final FDA approval before it can be sold.

FDA record · November 2026

Where a generic of Ozempic stands, date by date

What the FDA has approved so far, and the patent dates that still stand in the way.

  • FDA action
  • A GLP-1 generic is approved
  • Patent date in the Orange Book
  1. FDA approves Ozempic

    Novo Nordisk's semaglutide injection for type 2 diabetes (NDA 209637). Wegovy follows on June 4, 2021.

  2. First generic GLP-1 of any kind

    Generic exenatide, a copy of Byetta, from Amneal. The FDA's Orange Book now lists it as discontinued.

  3. First generic of Victoza (liraglutide)

    Approved for Hikma. A daily injection for type 2 diabetes.

  4. Semaglutide shortage resolved

    The FDA takes semaglutide injection off its shortage list.

  5. First generic of Saxenda (liraglutide)

    Approved for Teva. The first generic GLP-1 approved for weight management.

  6. Tentative approval for Apotex's semaglutide

    A generic semaglutide injection in the strengths of Ozempic's pens. A tentative approval does not allow sales.

  7. Still no generic of Ozempic, Wegovy or Rybelsus on sale

    The FDA has approved 12 generic liraglutide applications: 9 rated to Victoza and 3 to Saxenda.

  8. Main semaglutide patent ends

    US Patent 8,129,343, listed for Ozempic, Wegovy and Rybelsus.

  9. Last patent listed for Ozempic and Wegovy

    Later patents cover forms, devices and uses. Final FDA approval of a generic waits until patent issues are resolved.

Sources: Drugs@FDA and Orange Book data (ANDA 220314; NDA 209637; patent and exclusivity lists), FDA First Generic Drug Approvals 2024 and 2025, FDA news release of December 23, 2024, FDA compounding policy page. Checked November 2026.

Generic semaglutide in the US: one tentative approval, no final approval, and a main patent that runs to December 5, 2031. Generic liraglutide has been approved since December 2024.

Which GLP-1 Medicines Have a Generic?

Two older GLP-1 medicines do, and both are injected daily or twice daily rather than once a week. The FDA approved the first generic GLP-1, a copy of Byetta® (exenatide), on November 19, 2024 (FDA first generics, 2024). Liraglutide followed a month later.

Brand (medicine)First generic approved (generics approved by Nov 2026)
Byetta (exenatide)November 19, 2024 (1, now listed as discontinued)
Victoza (liraglutide), type 2 diabetesDecember 23, 2024 (9)
Saxenda (liraglutide), weight managementAugust 27, 2025 (3)
Ozempic, Wegovy, Rybelsus (semaglutide)None (1 tentative approval)
Zepbound®, Mounjaro® (tirzepatide)None

The first generic of Victoza went to Hikma (FDA news release), and the first generic of Saxenda went to Teva, the first generic GLP-1 approved for weight management (FDA first generics, 2025). The Orange Book rates each liraglutide generic against one of the two brands, so a generic of Victoza is not listed as a copy of Saxenda. Prices for generic liraglutide depend on the pharmacy and your plan.

Liraglutide is a different medicine from semaglutide, taken once a day. Our Saxenda vs Wegovy comparison covers how the two compare. For tirzepatide's patent dates, see tirzepatide vs Zepbound.

Is Compounded Semaglutide a Generic?

No. Compounded semaglutide is prepared by a licensed compounding pharmacy for one patient's prescription. It is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality, and it is not a generic or the brand product. On February 6, 2026, the FDA said companies may not claim that compounded drugs are generics of, or the same as, FDA-approved drugs.

Whether the compounded medicine is a generic is one of the questions people ask us before they start. Here is how the two differ:

  • An FDA-approved generic is approved through an ANDA after the FDA reviews it for safety, effectiveness and quality, and it must be shown bioequivalent to the brand. A drug maker makes it for any prescription. None is sold for semaglutide in the US today.
  • Compounded semaglutide has no FDA approval or FDA review, and it doesn't have to be shown bioequivalent to the brand. A licensed pharmacy prepares it for one patient's prescription. It is available in the US with a prescription.

For where compounded semaglutide stands legally and how to check a pharmacy, see is compounded semaglutide safe?

Is Generic Semaglutide Sold in Canada?

Yes, but not for patients in the US. Health Canada's Drug Product Database lists generic semaglutide injections from Dr. Reddy's and Apotex as marketed since May 2026, and approvals for Aspen and Sandoz. These products are not FDA-approved. The FDA says that "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use" when those products are not approved for the US (FDA). The patents that hold back a US generic are US patents, so a launch abroad doesn't change the dates above.

How Can You Check a Generic Semaglutide Offer?

Four checks take a few minutes:

  1. Look it up on Drugs@FDA. Search "semaglutide." An approved generic shows an ANDA with a prescription marketing status. In November 2026 the only semaglutide ANDA shows "None (Tentative Approval)."
  2. Ask which pharmacy fills it. The FDA tells patients to fill prescriptions only at a state-licensed pharmacy.
  3. Watch for fakes. The FDA says it is aware of counterfeit Ozempic in the US, which can contain the wrong ingredient, too much, too little or none at all.
  4. Treat "generic" on a compounded product as a red flag. The FDA says sellers may not call compounded drugs generics, so a seller that does is not following the FDA's rules.

What Does Semaglutide Cost Without a Generic?

Without a generic, the maker sets the price. Novo Nordisk's prices as of November 2026 (NovoCare, list price, Wegovy):

OptionPrice
Ozempic list price$1,027.51 per pen
Ozempic self-pay, 0.25, 0.5 or 1 mg pen$349 a month
Ozempic self-pay, 2 mg pen$499 a month
Wegovy self-pay pens$349 a month ($399 for Wegovy HD)
Ozempic or Wegovy tablets, self-pay$149 to $299 a month, by dose
Commercial insurance that covers itAs little as $25 a month (savings of up to $100)

Self-pay purchases are processed outside your insurance and don't count toward your deductible. If your plan covers Ozempic for type 2 diabetes, the savings offer will usually cost less than any cash option. Our semaglutide cost guide explains insurance, savings offers and yearly totals.

If you pay cash for weight management, MaxLife offers compounded semaglutide for $89 a month, flat, the same price at every dose, with no membership fee. The price is all-inclusive: the medicine if prescribed, a free online consultation, free ongoing medical support, supplies and free expedited shipping. MaxLife is a patient management platform, not a pharmacy: a licensed provider reviews your intake and decides whether a prescription is right for you, and a licensed partner pharmacy prepares it. Compounded semaglutide is not a generic of Ozempic, and Ozempic's trial results have not been shown for it. To compare other online programs, see the cheapest semaglutide online.

How we made this page: we researched it from the sources listed below. The MaxLife operations team reviews every page before it goes live, and a licensed clinician also reviews our medical articles. Every FDA date and status on this page comes from fda.gov (Drugs@FDA, the Orange Book and FDA announcements), checked in November 2026.

Frequently Asked Questions

No generic of Ozempic is sold in the US yet. When one gets final FDA approval, it will have had to match Ozempic in active ingredient, strength, dosage form and route and to be bioequivalent, so the FDA expects it to have the same clinical effect and safety profile. Compounded semaglutide has not been through that review.
Probably, but no price is known yet. The FDA says a single generic competitor can lower prices by about 30%, and five competing generics are linked to price drops of nearly 85%. Until a generic gets final approval, Novo Nordisk sets the price of every FDA-approved semaglutide product.
No. As of November 2026 the FDA has not approved a generic of Wegovy, the injection or the pill. Wegovy shares the main semaglutide patent that runs to December 5, 2031, and the Orange Book lists other Wegovy patents as late as February 17, 2041.
No. Both are brand-name semaglutide tablets from Novo Nordisk, and the FDA lists them under the same new drug application. A generic tablet would need its own FDA approval, and none has one.
Ask your pharmacist. The FDA's Orange Book rates each liraglutide generic as equivalent to one brand: 9 generics are rated to Victoza and 3 to Saxenda as of November 2026. A generic of Victoza is not rated as a copy of Saxenda, so your prescription decides which one fits.
It is slang, not a medical term. Online it is used for supplements such as berberine and for older, cheaper medicines. None of them is a generic of Ozempic, and supplements are not approved by the FDA to treat obesity. If cost is the problem, ask your provider about FDA-approved options your plan covers or a lower-cost cash route.
Only if a licensed provider decides it is right for you. Compounded semaglutide is not a generic and is not FDA-approved. Through MaxLife it costs $89 a month, flat, the same price at every dose, with no membership fee, and a licensed partner pharmacy prepares it.

Compounded Semaglutide: $89/mo Flat, All-Inclusive

MaxLife compounded semaglutide: $89 a month, flat. All-inclusive, no membership fee, the same price at every dose. A licensed provider decides.

Check Your Eligibility

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results vary. Pricing, insurance coverage, and compounding regulations described here are subject to change; verify current details with your insurance provider, the manufacturer, or your prescriber before making treatment decisions. Compounded medications are not FDA-approved.

Sources

More on this topic